Current Report Filing (8-k)
18 November 2016 - 12:20AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 16, 2016
PROPHASE
LABS, INC.
(Exact
name of Company as specified in its charter)
Delaware
(State
or other
jurisdiction
of incorporation)
|
|
0-21617
(Commission
File
Number)
|
|
23-2577138
(I.R.S.
Employer
Identification
No.)
|
621
N. Shady Retreat Road
Doylestown,
PA
|
|
18901
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Company’s
telephone number, including area code:
(215) 345-0919
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
Other Events
On
November 16, 2016, ProPhase Labs, Inc. (the “Company”) issued a press release announcing that the arbitration case
that has been ongoing since October, 2014 with Phosphagenics, Inc. and Phosphagenics, LTD (collectively, “Phosphagenics”)
in connection with the Phusion Laboratories, LLC (“Phusion”) joint venture has been resolved and is now concluded.
The
arbitrator rejected all of the counterclaims asserted by Phosphagenics that the Company pay damages to Phosphagenics. The arbitrator
also awarded to the Company recovery of approximately $350,000 (net of the payment of certain wind down expenses) that had been
invested in the Phusion joint venture entity; terminated the intellectual property license that had been granted to Phusion from
Phosphagenics; and directed the wind down and termination of Phusion Laboratories LLC, the joint venture entity.
A
copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The
information in this Item 8.01 and Exhibits 99.1 shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under
the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated November 16, 2016
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ProPhase
Labs, Inc.
|
|
|
|
|
By:
|
/s/
Robert V. Cuddihy, Jr.
|
|
|
Robert V. Cuddihy,
Jr.
|
|
|
Chief Operating Officer
and
|
|
|
Chief Financial Officer
|
Date:
November 17, 2016
INDEX
TO EXHIBITS
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release issued November 16, 2016
|
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2024 to May 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From May 2023 to May 2024